Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism

• Status: Not yet recruiting
• Trial end date: 2026-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if additional interventions will assist with decreasing the risk and/or severity of thromboembolism (clotting complications) in patients who have experienced a major traumatic event.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Texas Health Science Center, Houston
• Collaborator: Grifols Therapeutics LLC

Criteria

Inclusion Criteria:

• Highest level of trauma activation or upgrade to highest level

• Polytraumatic injuries OR pelvic/long bone fracture

• Admission to trauma ICU or Surgical Intermediate Care Unit (SIMU)

• Informed consent obtained

Exclusion Criteria:

• Prisoners (defined as those directly admitted from correctional facility)

• Known or suspected pregnancy

• ≥ 20% total body surface area (TBSA) burned

• Nonsurvivable head injuries

• Known hematologic or immunologic disorders

• Known prehospital anticoagulant use

• Patients initially placed on unfractionated heparin for thromboprophylaxis

• Known allergy to Antithrombin or it's components

• Enrollment in another interventional study unless approved by Trial Principal Investigator